Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Given New $53.00 Price Target at Wedbush

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its price target hoisted by equities research analysts at Wedbush from $50.00 to $53.00 in a research note issued on Wednesday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Wedbush’s target price would suggest a potential upside of 21.84% from the company’s previous close.

A number of other research firms have also recently commented on KNSA. Wall Street Zen cut Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 2nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research report on Thursday, January 22nd. The Goldman Sachs Group boosted their price objective on Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Canaccord Genuity Group began coverage on shares of Kiniksa Pharmaceuticals International in a research report on Thursday, February 19th. They set a “buy” rating and a $62.00 target price on the stock. Finally, Zacks Research cut shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 13th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Kiniksa Pharmaceuticals International presently has a consensus rating of “Moderate Buy” and an average price target of $54.14.

Kiniksa Pharmaceuticals International Trading Down 8.2%

Shares of NASDAQ:KNSA opened at $43.50 on Wednesday. The firm has a 50 day simple moving average of $42.87 and a 200-day simple moving average of $39.64. Kiniksa Pharmaceuticals International has a twelve month low of $18.25 and a twelve month high of $49.12. The company has a market capitalization of $3.30 billion, a PE ratio of 96.67 and a beta of 0.06.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, February 24th. The company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.12). Kiniksa Pharmaceuticals International had a return on equity of 7.46% and a net margin of 6.01%.The company had revenue of $202.13 million for the quarter, compared to analyst estimates of $200.86 million. During the same quarter in the prior year, the business earned ($0.12) earnings per share. Kiniksa Pharmaceuticals International’s revenue was up 65.0% compared to the same quarter last year. As a group, equities research analysts predict that Kiniksa Pharmaceuticals International will post -0.55 EPS for the current fiscal year.

Insider Activity at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, COO Eben Tessari sold 12,048 shares of the business’s stock in a transaction on Monday, December 15th. The shares were sold at an average price of $41.56, for a total value of $500,714.88. Following the transaction, the chief operating officer directly owned 16,666 shares of the company’s stock, valued at approximately $692,638.96. The trade was a 41.96% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Mark Ragosa sold 42,841 shares of the firm’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $41.49, for a total transaction of $1,777,473.09. Following the completion of the sale, the chief financial officer owned 31,086 shares of the company’s stock, valued at $1,289,758.14. This trade represents a 57.95% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 123,623 shares of company stock worth $5,236,389 in the last three months. Insiders own 53.48% of the company’s stock.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Rubric Capital Management LP raised its stake in shares of Kiniksa Pharmaceuticals International by 2.3% during the 3rd quarter. Rubric Capital Management LP now owns 4,000,000 shares of the company’s stock worth $155,320,000 after buying an additional 90,194 shares in the last quarter. Vanguard Group Inc. raised its position in Kiniksa Pharmaceuticals International by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 3,112,937 shares of the company’s stock worth $128,409,000 after acquiring an additional 49,802 shares in the last quarter. Acadian Asset Management LLC raised its position in Kiniksa Pharmaceuticals International by 22.6% in the second quarter. Acadian Asset Management LLC now owns 1,267,989 shares of the company’s stock worth $35,067,000 after acquiring an additional 233,668 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in Kiniksa Pharmaceuticals International by 45.3% in the third quarter. Arrowstreet Capital Limited Partnership now owns 1,068,263 shares of the company’s stock valued at $41,481,000 after acquiring an additional 332,846 shares during the period. Finally, Qube Research & Technologies Ltd boosted its position in shares of Kiniksa Pharmaceuticals International by 277.8% during the 2nd quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock worth $24,581,000 after purchasing an additional 653,236 shares in the last quarter. Institutional investors and hedge funds own 53.95% of the company’s stock.

Key Kiniksa Pharmaceuticals International News

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

• Positive Sentiment: Company issued robust ARCALYST 2026 net product revenue guidance of $900M–$920M, signaling continued commercial traction and market penetration. GlobeNewswire: Financial Results and Guidance
• Positive Sentiment: Revenue momentum: Q4 ARCALYST net product revenue was $202.1M and full‑year ARCALYST revenue reached $677.6M (FY2025), and total company revenue grew ~65% YoY — evidence of strong commercial execution. GlobeNewswire: Revenue Details
• Neutral Sentiment: Pipeline timing: KPL‑387 Phase 2 recurrent pericarditis data expected in 2H‑2026 and a KPL‑1161 Phase 1 trial planned to start by end‑2026 — these are important catalysts but still months away. GlobeNewswire: Pipeline Update
• Neutral Sentiment: Unusual options activity has been noted by some outlets — could reflect speculation or hedging and may amplify intraday moves, but not a fundamental change. MSN: Options Activity
• Negative Sentiment: Q4 EPS missed expectations: reported $0.17 vs. consensus ~$0.29 — the EPS shortfall (and lower-than-expected profitability metrics) was the primary driver of the selloff despite revenue beating estimates slightly. Zacks: EPS Miss
• Negative Sentiment: Valuation and near‑term profitability concerns: the stock trades at a high multiple relative to current profitability (P/E elevated) and some analysts still expect negative FY EPS, making the name sensitive to execution and margin trends. MarketBeat: Stock Profile & Estimates

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.